- Report
- October 2024
- 200 Pages
Global
From €3413EUR$3,750USD£2,899GBP
- Report
- September 2024
- 121 Pages
North America
From €5416EUR$5,950USD£4,600GBP
- Report
- November 2022
- 230 Pages
Global
From €3413EUR$3,750USD£2,899GBP
- Report
- February 2023
- 30 Pages
Global
From €2503EUR$2,750USD£2,126GBP
- Report
- February 2022
- 269 Pages
Global
From €8647EUR$9,500USD£7,344GBP
- Report
- June 2023
- 27 Pages
Global
€11150EUR$12,250USD£9,470GBP
Eucrisa is a topical medication used to treat mild to moderate atopic dermatitis (eczema) in adults and children two years of age and older. It is a corticosteroid-free, non-steroidal, topical cream that works by blocking the release of certain inflammatory substances in the body. Eucrisa is the first and only FDA-approved topical medication for atopic dermatitis that does not contain a corticosteroid.
Eucrisa is a relatively new drug in the dermatological market, but it has quickly become a popular treatment option for those suffering from atopic dermatitis. It is a safe and effective alternative to corticosteroid-based treatments, and it has been shown to reduce the severity of symptoms and improve quality of life for those with atopic dermatitis.
The Eucrisa market is comprised of a variety of companies, including Pfizer, Inc., Galderma Laboratories, L.P., and Valeant Pharmaceuticals International, Inc. These companies are dedicated to providing safe and effective treatments for atopic dermatitis, and they are committed to helping those suffering from this condition. Show Less Read more